Use of natural killer cells in hematopoetic stem cell transplantation.
about
Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategiesHigh log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapySeparating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease.Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection.Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transferBiological response modifiers as adjuncts to stem cell transplantation.The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors.Potential therapeutic role of natural killer cells in cancer.Genetics of graft-versus-host disease: the major histocompatibility complex.Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation.Risk assessment in haematopoietic stem cell transplantation: histocompatibility.Current status of haploidentical stem cell transplantation for leukemia.Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cellsBone marrow T cells are superior to splenic T cells to induce chimeric conversion after non-myeloablative bone marrow transplantationNew frontiers in cell-based immunotherapy of cancer.Tumor immune therapy: lessons from infection and implications for cancer - can IL-7 help overcome immune inhibitory networks?Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance.Cytotoxic function of umbilical cord blood natural killer cells: relevance to adoptive immunotherapy.Natural killer cell immune escape in acute myeloid leukemia.Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.Chronic myeloid leukemia and allogeneic natural killer cells: a surprising dialogue.Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience.Granulocyte-colony-stimulatory factor: a strong inhibitor of natural killer cell function.Influence of autologous dendritic cells on the in-vitro expansion and functions of peripheral blood NK cells.Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens.Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
P2860
Q26996660-1B82BC4A-0080-4EC9-8ABA-B74F9BCF2005Q27334458-D33C9030-8F36-4D6F-8FB3-8D4F3DA67A7CQ33685495-910AB893-7DAB-40C1-AF7C-2E3C555605C1Q34077847-7EBAF8E3-957A-447D-A8EC-E48D909ABEB7Q34167845-9453C548-2C4C-4802-9B9C-00E4B881D363Q34577711-6886F5C1-2708-4E79-8E93-2642CAF1EB47Q35034803-4D53FC0A-4CA5-4547-A95D-463CEAE4845CQ35799180-DF0F83AC-CE6F-4767-804E-16836227469BQ36446933-FD2497D8-86CA-495C-B984-373EB49E3BD2Q36465501-3DD4FF95-DDF7-407B-82F0-C2F52306597AQ36675436-4B939D6C-AD56-4507-9743-6CEDA04AAD39Q36766250-BDC09F00-FFD3-4909-A55E-C7D01D90DE3AQ36795165-68A6E161-BBB3-41C9-8098-45AA2FEAB071Q36797744-C1F94BEC-115B-49FA-B228-993A0C151DE9Q37088557-8C48A311-7DFF-43C2-B83C-D1E1231B6E79Q37099383-2BB4F4E8-CB90-4CA8-84AE-4575E59620C9Q37320975-E4389180-84A5-4EE6-B264-4A14FF38ED8CQ37481361-4CC8DF38-1A3B-457F-A700-382A239753CCQ37762226-7C8613A2-89A3-4102-A1D4-B5833DE87B43Q37864686-4458E0C7-A081-4CEA-931B-6958D3FC8FBFQ37876089-0E5FECA7-ABDA-4D35-B8E8-14DCDF637479Q37942233-E6ED9EE4-D516-4F0D-80C9-3600B4EC7001Q37996816-282ACA75-0553-479F-96F6-2215E58E0EA5Q38285256-A3DA2256-37EA-4D40-9FEC-A1AA518A57C1Q38460376-E76D960F-96CF-4E17-A5D1-8C9B723C1408Q42428834-DBD8A44D-3C70-403A-A1F7-8695D7763153Q43061582-DD06923E-0FC5-493C-921A-4E5A417D3891Q43761885-192ED5B8-3929-4500-9396-9E2635AEE2F4Q49077913-FAEC027D-A005-4DCF-AA9E-7BCD100BE83DQ51034109-86CB0B36-BCC5-46EF-837D-C942121E62FCQ53119000-E25D7E12-79FD-4229-86F7-3B2DFA4F6D17Q53554158-77833105-10F4-4289-8990-C25345D7B10E
P2860
Use of natural killer cells in hematopoetic stem cell transplantation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Use of natural killer cells in hematopoetic stem cell transplantation.
@ast
Use of natural killer cells in hematopoetic stem cell transplantation.
@en
type
label
Use of natural killer cells in hematopoetic stem cell transplantation.
@ast
Use of natural killer cells in hematopoetic stem cell transplantation.
@en
prefLabel
Use of natural killer cells in hematopoetic stem cell transplantation.
@ast
Use of natural killer cells in hematopoetic stem cell transplantation.
@en
P2093
P2860
P356
P1476
Use of natural killer cells in hematopoetic stem cell transplantation.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704810
P407
P577
2005-04-01T00:00:00Z